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Azelastine hydrochloride (AZE) is an anti-allergic drug that 
inhibits the release of various chemical mediators from mast 
cells. We compared the immunosuppressive effects of AZE 
and FK-S06 in vivo and in vitro. Topical application of AZE 
strongly inhibited the efferent phase of contact hypersensi-
tivity, as did application of FK-S06. In in vitro experiments, 
we found that 1) the suppression by AZE on interleukin 
(IL)-2 production from splenic T cells was partial and con-
siderably large amounts of IL-2 were still produced, even in 
the presence of 10-5 M of AZE, which was in sharp contrast 
to the observed marked inhibition of [3H]_ TdR incorpora-
tion; 2) AZE significantly inhibited the phorbol myristate 
acetate-induced IL-2 responsiveness; 3) AZE did not inhibit 
the IL-2 receptor a expression of activated T cells; and 4) the 
significant inhibitory action was still observed even when 
AZE was added at 48 h after the initiation of culture. In 
A zelastine hydrochloride (AZE; C22H24ClN3o' HCI, MW = 418.37) (Fig 1) is an anti-allergic drug that inhibits allergic bronchospasms and passive cutaneous anaphylaxis in rats and guinea pigs [1,2]. AZE has potent histamine HI-receptor - blocking properties 
[1,3]' AZE als.o exerts strong inhi~itory effect.s on .the release of 
chemical mediators such as leukotnenes and hlstamme from mast 
cell [2,4]' In addition, AZE possesses leukotriene and serotonin re-
ceptor-blocking activities [1,2]. Based on these findings, AZE is 
now used widely in Japan as an effective and long-acting anti-aller-
gic drug for the treatment of atopic disorders such as asthma, aller-
gic rhinitis, and atopic dermatitis. In the screening of the immuno-
modulatory roles of various agents, we found that AZE had potent 
immunosuppressive effects. The present study was undertaken first 
to investigate whether the topical application of AZE has a capacity 
to inhibit contact hypersensitivity itl vivo, and second, to character-
ize the immunosuppressive activity of AZE in vitro, in comparison 
with the well-characterized immunosuppressant FK-S06. The re-
sults show that topical application of AZE strongly inhibits the 
efferent phase of contact hypersensitivity, and that AZE exerts its 
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regard to FK-506, we found that 1) FK-506 completely 
blocked the production of IL-2; 2) exogeneous IL-2 consist-
ently restored the FK-506-induced inhibition; 3) FK-506 
affected the phorbol myristate acetate - induced IL-2 respon-
siveness very little, if any; and 4) the significant suppression 
was observed only when FK-506 was added within 24 h after 
the initiation of culture. Thus, AZE exerts its ill vitro immu-
nosuppressive activity preferentially by interfering with the 
IL-2 responsiveness, with partial inhibition of IL-2 produc-
tion. Conversely, FK-506 acts as a strong inhibitor of IL-2 
production without a prominent effect on IL-2 responsive-
ness. The immunosuppressive activity of AZE shown in vitro 
may also be operative ill vivo and may be applicable for topical 
use. Key words: azelastine/FK-506/immu11osuppression/contact 
hypersensitivity/IL-2 responsiveness. ] II1Vest DermatoI103:49-
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immunosuppressive activity preferentially by interfering with in-
terleukin (IL-2) responsiveness, with partial inhibition of IL-2 pro-
duction, which is distinct from the results observed with FK-S06. 
MATERIALS AND METHODS 
Animals C3H/HeN and Balb/c mice were obtained from the Shizuoka 
Agricultural Cooperative Association for Laboratory Animals, Hamamatu, 
Japan. 
Reagents AZE was obtained from the Eisai Co., Tokyo, Japan. FK-506 
was obtained from the Fujisawa Pharmaceutical Co., Osaka, Japan. 
Concanava!!n A (Con A) and phorbol myristate acetate (PMA) were pur-
chased from Sigma. lonomycm was purchased from Calbiochem, La Jolla, 
CA. Anti-IAk monoclonal antibody was obtained from culture supernatants 
of the 10.2.16 hybndoma (mouse IgG2b, American Type Culture Collec-
tion~ Rockville, ~D). Fluorescein isothiocyanate (FITC) -conjugated anti-
mUrIne mterleukm 2 (IL-2) receptor 0: monoclonal antibody (7D4, rat im-
muno~lobulin [Igl~) and FITC-c?njugated rat IgM were purchased from 
P~armmgen, San Diego, CA. Antl-Thy1.2 antibody (Rat IgG2b) was ob-
tamed from Beckton Dlckmson, San Jose, CA. FITC-conjugated goat anti-
mouse IgG was ~urchased from Cappel, West Chester, PA. FITC-conju-
gated sheep anti-rat IgG2b was purchased from The Binding Site, 
Blrmmgham, U .K. Munne recombinant interleukin 2(MrIL-2) was ob-
tained from Genzyme, Cambridge, MA. 
Effects of Drugs on Contact Hypersensitivity In Vivo AZE and FK-
506 were dissolved in 2: 1 dimethylsulfoxide (DMSO) : ethanol to a con-
traction of 3.3% (w/v, 0.079M) and 1 % (w/v, 0.012M), respectively. 
C3H mice were sensitized by the epicutaneous application of 1 00 jll of7% 
2,4,6-trinitro-chlorobenzene (TNCB; ICN Pharmaceuticals, Inc., Plain-
view, NY) in 4 : 1 acetone: olive oil, as previously described [5]. Seven days 
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4- (p-chlorobenzyl) -2- (hexahydro-l-methyl-lH-
azepine-4-y 1) -1- (2H) -phthalazinone hydrochloride 
Figure 1. Structure of azelastine. 
after painting, 30 J.ll of either the AZE solution, FK-S06 solution, or diluent 
control (2: 1 DMSO: ethanol) were applied topically on the left ear. The left 
ear was subsequently challenged with a total of 20 J.l1 of 1 % TNCB in olive 
oil 60 min later. Ear thickness was quantified with a micrometer (Mitsutoyo 
Co., Tokyo,Japan) 24 h later by comparing the thickness of the same left ear 
prior to challenge. 
['H_ TdR] Incorporation of Accessory Cell-Dependent T-Cell Stim-
ulation Assay Complete medium used was RPMI 1640 supplemented 
with 10% fetal calf serum (Gibco, Grand Island, NY), 100 U /ml penicillin, 
100 J.lg/ml streptomycin, and 0.25 J.lg/ml amphotericinB. AZE and FK-S06 
were dissolved in DMSO at a concentration of 10-2 M and 10-3 M, respec-
tively. These stock aliquots were used to prepare various concentrations of 
the agents in complete medium. The DMSO diluents were diluted in paral-
lel to serve as solvent control. 
Murine splenocytes (4 X 105 cells/well) were cultured with 5 J.lg/ml of 
Con A for 72 h in a 96-well flat-bottomed microculture plate in triplicate 
(total, 0.2 ml) with solvent control, AZE, or FK-506. Cultures were pulsed 
with 1 J.lCi of ['H]-TdR (ICN Biomedicals, Irvine, CA) for the last 16-
18 h. 
In the timecourse experiment, AZE, FK-506, or solvent control were 
added at 0,24, and 48 h after the initiation of culture and [3H]-TdR incorpo-
ration was assayed. Percentage inhibition was calculated according to the 
following formula: 
% inhibition 
_ cpm of culture with solvent control - cpm of culture with drug 
- cpm of culture with solvent control - cpm of background culture 
X 100 (%). 
I'H-TdR] Incorporation of Accessory Cell-Independent T-Cell 
Stimulation Assay T cells were purified from splenocytes after they were 
passed over a nylon wool column and treated with anti-I-A antibody plus 
complement (6]. The resulting purified Tcells contained> 95% Thy-l +and 
< 0.2% Ia+ cells, as identified by immunofluorescence. T cells (1 X 105 
cells/well) were stimulated with PMA (10 ng/ml) plus ionomycin (200 
ng/ml) for 72 h in 96-well plates in triplicate (total, 0.2 ml/well) with 
solvent control, AZE, or FK-506. All cultures were pulsed with 1 J.lCi of 
(3H]_ TdR for the last 16 -18 h. 
Restoration of the Drug-Induced Inhibition by MrIL-2 To examine 
the restorative activity of MrIL-2, 100 U/ml of MrIL-2 was added to the 
culture with AZE or FK-506, and T-cell proliferative response was assayed 
by ['HJ-TdR incorporation in accessory cell-dependent or -independent 
assay. 
PMA-Induced IL-2 Responsiveness The purified T cells were activated 
with MrIL-2 (50 U /ml or 150 U/ml) in the presence ofPMA (10 ng/ml) for 
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Ear Thickness (x 10- ' mm) 
Sensitization Elicitation 1 2 3 4 5 6 7 8 9 10 
TNCB Diluents TNCB 
TNCB AZE (3.3 %) TNCB 
* 
TNCB FK-506 (1 %) TNCB 
* 
Diluents TNCB 
Figure 2. Effects of AZE and Fk-S06 on the contact hypersensitivity itl vivo 
by topical application. C3H mice were sensitized epicutaneously with 7% 
TNCB and 7 d later ears were challanged with 20/11 of 1 % TNCB and ear 
swelling was measured. One hour before challanging, ears were applied 
with 30 J.ll of 3.3% AZE, 1 % FK-506, or diluent control (DMSO: eth-
anol = 2: 1).· P < 0.01. 
72 h with or without drugs, and (3H]-TdR incorporation was assayed as 
described above. 
IL-2 Production Assay Culture supernatants were collected at 24 h after 
the initiation of culture. The IL-2 - sensitive T-cell line CTLL (5 X 10' 
cells/well) was incubated with serially diluted culture supernatants for 24 h 
and pulsed with 1 J.lCi of (3H]_ TdR for the last 6 h, as described previously 
[7J. IL-2 production (U /ml) was quantitated from the positive control curve 
using MrIL-2. In this bioassay, neither AZE nor FK-506 had any effect on 
the proliferation of CTLL up to the diluted concentration examined. 
Effects of Drugs on PMA-Induced IL-2 Receptor a Expression Pur-
ified T cells were activated by 10 nglml ofPMA with or without drugs for 
24 h as described above, and were stained with FITC-conjugated anti -IL-2 
receptor a antibody or control FlTC-conjugated rat IgM. 
The stained T cells were analyzed using the EPICS Profile Analyzer, 
Coulter Corp. 
Statistical Analysis The Student t test was used to compare results. A p 
value of less than 0.05 was considered to be significant. 
RESULTS 
Effects of AZE and FK-S06 on the Contact Hypersensitivity 
In Vivo by Topical Application We first analyzed the effects of 
topical application of AZE on the contact hypersensitivity in vivo. 
We used FK-S06 as an effective drug control. The immunosuppres-
sive activity of topical FK-S06 has been reported previously [8]. 
C3H mice were epicutaneously sensitized with 7% TNCB. Seven 
days later, 30 fll of either 3.3% (0.079 M) AZE, 1% (0.012 M) 
FK-S06, or diluent control was applied on the ear that was further 
painted with 1 % TNCB 1 h later. The immunosuppressive effect of 
AZE or FK-S06 was evaluated by measuring ear thickness. The 
single application of AZE or FK-506 strongly inhibited the ear 
swelling (Fig 2). In three independent experiments the percentages 
of inhibition by AZE were 83.9%, 88.3%, and 100%, respectively. 
Effects of AZE and FK-506 on [3H]-TdR Incorporation in 
Accessory Cell-Dependent T-Cell Stimulation Assay W e 
examined the effects of AZE and FK-S06 on the viability of unstim-
ulated splenocytes in vitro. The viability of unstimulated splenocytes 
was not affected significantly by AZE (up to 10-5 M) or FK-S06 (up 
to 10-8 M) after 72 h incubation when compared with solvent con-
trol or medium only (data not shown). We next examined the 
effects of AZE and FK-S06 on the proliferation of splenocytes stim-
ulated with Con A. Both AZE and FK-506 dose-dependently inhib-
ited the [3H]_ TdR incorporation of splenocytes (Fig 3). Average 
SO% effective dose (ED50) of AZE was 3.3 X 10-6 M in C3H mice 
and 4.8 X 10-6 M in Balbi c mice. The average ED50 ofFK-S06 was 
5 X 10-10 Min C3H mice and 5.9 X 10-10 Min Balb/c mice, re-
spectively. 10-5 M of AZE and 10-8 M of FK-506 showed the 
similar range of percent inhibition on the (3H]-TdR incorporation 
(percent inhibition: AZE, 90.S ± 2.1%; FK-S06, 89.9 ± 1.5%). 
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F" ure 3. Effects of AZE and FK-506 on [3H]_ TdR incorporation in acces-s~;;' cell- dependent. T-cell stimulation assay. Splenocytes (C3H) were acti-
ated with Con A III the presence of vanous concentratIOns of AZE or 
;K-S06. and [3H]-TdR incorporation was assayed. • p < 0.01; •• P < O.OOL 
o solvent control for AZE; •• AZE; fl. solvent control for FK-S06; "", 
FK-S06. 
Tirnecourse of AZE- or FK-S06-Induced Inhibition AZE, 
FK-506. or solvent control was added at 0, 24, or 48 h after the 
initiation of culture, and percent inhibition was compared in Con 
A - induced proliferation of splenocytes. The inhibitory activity of 
FK-S06 declined rapidly as the time added became later, whereas 
AZE still retained high inhibitory action even when added at 48 h 
later (percent inhibition by the addition of drugs at 0, 24, and 48 h 
later: AZE, 97%, 88%, 53.8%; FK-S06, 93.4%, 73.5%, 15.8%). 
Effects of AZE and FK-506 on the IL-2 Production in Acces-
sory Cell-Dependent T-Cell Stimulation Assay The splen-
ocytes were stimulated with Con A in the presence of AZE, FK-S06, 
and solvent control, and IL-2 production was assayed. The effects of 
AZE and FK-S06 on the [3H]_ TdR incorporation were also exam-
ined at the same time. As shown in Table I, FK-S06 completely 
inhibited the IL-2 production at a concentration of 10- 8 M. Al-
though AZE (10- 5 .M) significantly inhibited IL-2 prod~ction, the 
inhibition was partial and large amounts of IL-2 were stdl secreted 
by Con A - stimulated splenocytes, even in the presence of AZE. In 
contrast, the inhibitory activity of AZE on the [3H]_ TdR incorpora-
tion was again as potent as that of FK-S06. 
Restoration of the Immunoinhibitory Action of AZE and 
FK-S06 in the Accessory Cell-Dependent Assay We next 
investigated whether some exogeneous factor(s) could counteract 
the inhibitory activities of AZE or FK-S06. Because considerably 
large amounts of IL-2 were still produced even in the presence of 
AZE, whereas there was complete suppression of IL-2 production 
by FK-S06, we assumed that exogeneous IL-2 may counteract the 
inhibitory action ofFK-S06, but not that of AZE, This was the case, 
as shown in T able II. W e added MrIL-2 (100 U/ml) to the culture. 
and the restorative property of MrIL-2 was examined. MrIL-2 par-
tially but significantly restored the FK-S06- but not the AZE -
induced inhibition. 
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Effects of AZE and FK-S06 on [3H]_ TdR Incorporation and 
IL-2 Production in the Accessory Cell- Independent T -Cell-
Stimulation Assay To examine the direct effects of drugs on T 
cells, purified T cells were activated by PMA + ionomycin stimula-
tion in the presence or absence of AZE or FK-S06. Consistent with 
the results of Con A-induced proliferation of splenocytes, both 
AZE and FK-506 directly inhibited the [3H]_ TdR incorporation of 
T cells activated by PMA + ionomycin stimulation (Table III) . 
With regard to IL-2 production, FK-506 completely abrogated the 
IL-2 production from T cells stimulated by PMA + ionomycin, 
whereas AZE showed only mild inhibitory activity on the IL-2 
production. 
Again, exogeneous MrIL-2 had no significant restorative activity 
on AZE-induced immunosuppression . However, FK-506 - induced 
immunosuppression was restored completely by the addition of 
MrIL-2 (Table III). Compared with the accessory cell - dependent 
stimulation assay, the restorative activity ofMrIL-2 was much more 
prominent in the accessory cell - independent T -cell- stimulation 
assay, suggesting that FK-506 has some inhibitory activity not only 
for T cells but also for accessory cells, and that the restorative activ-
ity of MrIL-2 acts mainly on T cells . 
Effects of AZE and FK-S06 on PMA-Induced IL-2 Respon-
siveness of Purified T Cells W e next examined the effects of 
AZE and FK-S06 on the PMA-induced IL-2 responsiveness of puri-
fied T cells (Table IV). AZE strongly inhibited PMA-induced IL-2 
responsiveness in either higher (150 U /ml) or lower (50 U/ml) 
concentrations of MrlL-2. On the contrary, FK-S06 affected the 
PMA-induced IL-2 responsiveness very little, if any, which was in 
sharp contrast to the marked inhibition of IL-2 production by FK-
506. These data indicate that AZE exerts its immunosuppressive 
activity mainly by interfering with th e IL-2 responsiveness, whereas 
FK-S06 acts as a strong inhibitor of IL-2 production. 
Effects of AZE and FK-506 on the IL-2 Receptor a (CD25) 
Expression of Activated T Cells We next examined the effects 
of the drugs on IL-2 receptor a expression by use of activated T 
cells. Purified T cells were activated by 10 nglml ofPMA and the 
CD2S expression was compared in the presence or absence of the 
drugs. 
Solvent control (DMSO) per se had a greater tendency to increase 
CD2S expression than did the control medium. However, neither 
AZE nor FK-S06 significantly affected the CD2S expression when 
compared to solvent control (Fig 4). These data indicate that the 
AZE.induced inhibition of IL-2 responsiveness is likely to exist , 
irrespective of its receptor expression. 
DISCUSSION 
W e compared the immunosuppressive effects of AZE and FK-506 
in vivo and ill "itro. The single topical application of 3.3% of AZE 
(0.08 M) strongly inhibited the efferent phase of comact hypersen-
sitivity, as did topical FK-S06. The inhibitory action of topical 
FK-S06 on contact hypersensitivi ty has already been documented 
by Meingassner et al. They reported that topical application of 
0.04 - 0.4% FK-S06 solution significantly inhibited the skin red-
Table I. Effects of AZE and FK-S06 on the IL-2 Production by Splenocytes Stimulated by Con A" 
Experiment 1 Experiment 2 Experiment 3 
Con A + solvcnt control (10- 5) 75.2b (88.010)' 3S.2 (S6.324) 48 .0 (45,271) 
Con A + AZE to- 5 M 2S.6 (12.0S0) 10.0 (3,423) 1S.2 (2,79S) 
Con A + solvcnt control (10- 8) 70.4 (100.611) 34.4 (56,745) 51.6 (60.175) 
Con A + FK-S06 to-8 M < 0.2 (8,246) < 0.2 (3,81S) < 0.2 (S.680) 
Con A NDJ 47.2 (S4,866) 51.2 (59,629) 
< 0.2 (lS5) < 0.2 (183) < 0.2 (157) 
• Splenocytes were stimulated by Con A with AZE (10- 5 M) . FK-S06 (10- 8 M) . or solvent control. and IL-2 production or ['HJ-TdR incorporation was assayed simulta neously. 
• IL-2 production (mea" U / ml) . 
, [>H-TdRj incorporation (mea" cpm). 
J Not done. 
52 FURUE ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
Table II. Restoration of lmmunoinhibitory Action of AZE and FK-506· 
Experiment 1 Experiment 2 Experiment 3 
Con A + solvent control (10- 5) 
Con A + AZE 10- 5 M 
Con A + AZE 10- 5 M + MrIL-2 (100 U/ml) 
Con A + solvent control (10- B) 
Con A + FK-506 10- 8 M 


























• Splenocytes were activated by Con A with drugs or solvent control in the presence or absence of MrIL-2 (100 U/ml). 
• ['H-TdR) incorporation (m ea" cpm). 
dening reaction induced by contact hypersensitivity to dinitrofluor-
obenzene in pigs [8]. Hanada et al have described that topical appli-
cation of 0.1- 5% AZE solution significantly inhibited the 
ultraviolet B - induced erythematous reaction in guinea pigs [9]' 
To know whether AZE has an ability to modulate the function of 
immunocompetent cells, we next compared the in vitro immuno-
suppressive effects of AZE and FK-506 using the accessory cell -
dependent or -independent T-cell activation assay. We found that 
1) AZE inhibited the [3H]-TdR incorporation in a dose-dependent 
manner; 2) the suppression of IL-2 production was partial and con-
siderably large amounts of IL-2 were still produced, even in the 
presence of 10- 5 M of AZE, which was in sharp contrast to the 
marked inhibition of[3H]-TdR incorporation; 3) AZE significantly 
inhibited the PMA-induced IL-2 responsiveness; 4) the inhibitory 
action was not restored by MrIL-2; 5) AZE did not inhibit the CD25 
expression of T cells; and 6) the significant inhibitory action was 
still observed even when AZE was added at 48 h after the initiation 
of culture. 
With regard to FK-506, the immunosuppressive mechanism(s) 
was likely to be due to the inhibition ofIL-2 production, because 1) 
FK-506 completely blocked the production ofIL-2; 2) exogeneous 
IL-2 consistently restored the FK-506-induced inhibition; 3) the 
significant suppression was observed only when FK-506 was added 
within 24 h after the initiation of culture; 4) FK-506 affected the 
PMA-induced IL-2 responsiveness very little, if any. 
Thus our data demonstrate that AZE exerts its immunosuppres-
sive activity preferentially by interfering with the IL-2 responsive-
ness with partial inhibition oflL-2 production, and conversely FK-
506 acts as a strong inhibitor ofIL-2 production without prominent 
Table III. Effects of AZE and FK-506 on the Proliferation of 
Purified T Cells Activated by PMA + Ionomycin· 
[3HJ-TdR IL-2 
Incorporation Production 
PMA + ionomycin + solvent 167,158' 86.4' 
control (10- 5) 
PMA + ionomycin + AZE 10- 5 M 30,700 76.8 
PMA + ionomycin + AZE 10-5 M + 19,601 NO 
MrIL-2 (100 U/ml) 
PMA + ionomycin + solvent 166,567 96.0 
control (10- 8) 
PMA + ionomycin + FK-506 10- 8 M 2,646 < 0.2 
PMA + ionomycin + FK-506 lO- B M + 173,867 NOJ 
MrIL-2 (100 U/ml) 
PMA + ionomycin 159,918 51.2 
PMA 1,736 < 0.2 
Ionomycin 152 < 0.2 
154 < 0.2 
• Purified T cells were activated by PMA + ionomycin stimulation in the presence of 
drugs or solvent control. and ['H]-TdR incorporation and 1L-2 production was exam-
ined. The restorative activity of MrlL-2 (100 V/ml) was also checked. Data arc repre-
sentative of cwo experiments. 
'Mean cpm. 
'Mean U/ m!. 
J NO, not done. 
effect on IL-2 responsiveness. The different immunosuppressive 
mechanism between AZE and FK-506 may explain the fact that 
AZE is still inhibitory, even at 48 h after the T-cell activation, 
whereas T-cell proliferation is induced by the engagement of the 
IL-2 receptor with already produced IL-2 by an autocrine mecha-
nism. Our results on the immunosuppression by FK-506 are in good 
accordance with those reported previously [10,11]. 
Todoroki et at reported that AZE inhibited the antigen-specific 
IL-2 responsiveness of human peripheral blood mononuclear cells 
[12] . They reported that the adherent cell population was more 
susceptible to the inhibitory action by AZE. Further studies are 
necessary to clarify whether AZE has a capacity to modulate the 
function of antigen-presenting cells such as Langerhans cells. 
The cellular binding site or binding molecule for AZE is unclear. 
Akagi et at reported the possibility that AZE may be internalized in 
the lipid bilayer of the cell membrane and stabilize the membrane-
associated signal transduction using a dipalmitoylphosphatidylcho-
line liposome model [13,14]. The membrane-stabilizing activity of 
AZE was further demonstrated by erythrocyte lysis assay. Suzaki et 
at showed that 3 X 10-6 M to 3 X 10- 5 of AZE inhibited hypoosmo-
tic lysis of red blood cells in a dose-dependent manner [15]. Because 
AZE did suppress IL-2 responsiveness without inhibiting the ex-
pression of IL-2 receptor a, AZE-induced inhibition of IL-2 
responsiveness may be attributable to the uncharacterized mem-
brane-stabilizing activity. Alternatively, AZE may possibly inhibit 
Table IV. Effects of AZE and FK-506 on the PMA-Induced 
IL-2 Responsiveness· 
PMA + MrlL-2 (50 U/ml) + 
solvent control (10- 5) 
PMA + MrIL-2 (50 U/ml) + 
AZE 10-5 M 
PMA + MrIL-2 (150 U/ml) + 
solvent control (10- 5) 
PMA + MrIL-2 (150 U/ml) + 
AZE 10- 5 M 
PMA + MrIL-2 (50 U/ml) + 
solvent control (1O-B) 
PMA + MrIL-2 (50 U/ml) + 
FK-506 to-8 M 
PMA + MrIL-2 (150 U/ml) + 
solvent control (10-B) 
PMA + MrIL-2 (150 U/ml) + 
FK-506 10- 8 M 
PMA + MrIL-2 (50 U/ml) 































• Purified T cells were stimulated with PMA (10 ng/ml) plus MrlL-2 (50 V/ml or 
150 U/rnI) and the inhibitoty effects of AZE or FK-506 were examined on ['H]-TdR 
incorporation. The restorative activity of MrlL-2 (100 U /ml) was also examined. 
• ['H]-TdR incorporation (me." cpm). 
, NO. not dOlle. 




Figure 4. Effects of AZE and FK-S06 on the IL-2 receptor <l' (CD2S) 
expression of act.ivated T cells. Purified T cell s wereactivated by 10 ng/ml of 
PMA with or without drugs for 24 h, and were stamed with control FITC-
conjugated rat IgM (A) or FITC-conjugated anti-IL-2 receptor <l' antibody 
(B-F). B) medium control; C) SOL 10~s; D) AZE lO-sM; E) SOL 10-8; 
1') FK-S06 10-8 M. Data are representative of two expenments. 
the expression or function of IL-2 receptor p or y of activated 
T cells. 
The immunosuppressive activity was not observed by another 
anti-allergic drug, tranilast (N-3, 4-dimethoxycinnamoyl anthrani-
lic acid), which is known to inhibit only release, but not receptor 
binding, of chemical mediators from mast cells (data not shown). 
Although AZE has distinct immunosuppressive activities itl vitro, 
a much higher dose is necessary for AZE (10-5 M) than for FK-506 
(10-9 M). The therapeutical serum concentration of AZE after oral 
administration of 2 mg / d is only as high as 3 X 10-9 M. Even 
though the tissue level of AZE is reported to be 30 - 40 times higher 
than serum level, 10-5 M of AZE seems to be far beyond the range of 
IMMUNOSUPPRESSIVE EFFECTS OF AZELASTINE 53 
concentration obtained by systemic administration in clinical use. 
Therefore, we first assessed the effect of AZE on contact hypersen-
sitivity by topical application where high local concentration of 
AZE would be expected. The strong inhibitory action of AZE on 
contact hypersensitivity suggested that the immunosuppressive ac-
tivity shown in vitro may be operative in vivo. Further studies are 
necessary to know whether topical AZE also inhibits the afferent 
phase of contact hypersensitivity. 
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